Please login to the form below

Not currently logged in
Email:
Password:

Juno

This page shows the latest Juno news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... Notably, Juno’s second most advanced candidate is a BCMA-targeting

Latest news

More from news
Approximately 11 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017 (liso-cel), CD19-directed CAR-T in pivotal trials for DLBCL.

  • Deal Watch November 2016 Deal Watch November 2016

    Winding back two years, Juno enjoyed the biggest Nasdaq IPO of 2014 raising around $265m at $24 per share. ... At the end of this November Juno shares were trading at around $20 per share and to date they have not recovered.

  • Deal Watch April 2016 Deal Watch April 2016

    61. Celgene (US). Juno (US). Option exercised to extend territory. Phase II CD19-based CAR T therapies for treatment of leukaemias.

  • Pharma deals in July 2015 Pharma deals in July 2015

    It still sounds like a high price but perhaps it is in Celgene'sDNA because only a month ago it bought shares in Juno Therapeutics at over a 100% premium in

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... and commercialisation in the rest of the world, and will pay Juno a royalty on sales in those territories.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... Notably, Juno’s second most advanced candidate is a BCMA-targeting

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Juno Therapeutics names Cindy Elkins as CIO. She joins the biopharma from Genentech, where she was VP of IT. ... She said: “I am delighted to join Juno, a company that reflects my passion for vibrant, accountable, high-performing organisations seeking

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics